A Non-interventional, Multi-centre Study to Investigate the Change in Clinical and Patient-reported Outcomes in Moderate to Severe COPD Patients Treated With TRIXEO (Budesonide / Glycopyrronium / Formoterol) Under Real-life Conditions
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms RECORD
- Sponsors AstraZeneca
Most Recent Events
- 11 Sep 2024 Status changed from active, no longer recruiting to completed.
- 14 Jun 2024 Planned End Date changed from 30 Jun 2024 to 12 Oct 2024.
- 14 Jun 2024 Planned primary completion date changed from 30 Jun 2024 to 12 Oct 2024.